Pfizer
is set to report its earnings on Tuesday, a week and a half after an executive told investors that the company was considering a list price for its Covid-19 vaccine of between $110 and $130 per adult dose, higher than analysts had expected.
The surprise has led analysts to rethink their estimates for next year’s Covid-19 vaccine sales, and raised questions about how to think about
Pfizer
long-term prospects. The company will have an opportunity to address those issues at an investor call scheduled for 10 a.m. on Tuesday. Financial results for the company’s third quarter will come before the market opens.
